VKTX241220C95000
- 0.05
- 0.000.00%
Viking Therapeutics Newsroom
Is Viking Therapeutics, Inc. (VKTX) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Viking Therapeutics, Inc. (VKTX) Stock Moves -1.75%: What You Should Know
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Viking Engineering Laboratory Achieves ISO 17025 Accreditation
10 Health Care Stocks With Whale Alerts In Today's Session
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
Promising Prospects for Viking Therapeutics' VK2735 in Obesity Treatment: A Buy Rating With $125 Price Target
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
Corbus, Viking Initiated at Overweight by Piper Sandler
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Piper Sandler Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $74
Piper Sandler Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $74
Express News | Viking Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $74
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline